

## Recent trends in the epidemiology of non-typhoidal *Salmonella* in Israel, 1999–2009

R. BASSAL<sup>1,13</sup>, A. REISFELD<sup>2</sup>, N. ANDORN<sup>2</sup>, R. YISHAI<sup>2</sup>, I. NISSAN<sup>2</sup>,  
V. AGMON<sup>2</sup>, N. PELED<sup>3</sup>, C. BLOCK<sup>4</sup>, N. KELLER<sup>5</sup>, Y. KENES<sup>6</sup>, D. TARAN<sup>7</sup>,  
B. SCHEMBERG<sup>7</sup>, S. KEN-DROR<sup>8</sup>, T. ROUACH<sup>9</sup>, B. CITRON<sup>10</sup>, E. BERMAN<sup>11</sup>,  
M. S. GREEN<sup>12</sup>, T. SHOHAT<sup>1,13</sup> AND D. COHEN<sup>1,13\*</sup>

<sup>1</sup> Israel Center for Disease Control, Ministry of Health, Tel Hashomer, Israel; <sup>2</sup> Central Salmonella Laboratory, Public Health Services, Ministry of Health, Jerusalem, Israel; <sup>3</sup> Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; <sup>4</sup> Hadassah Medical Centers, Jerusalem, Israel; <sup>5</sup> Chaim Sheba Medical Center, Tel-Hashomer, Israel; <sup>6</sup> Haemek Medical Center, Afula, Israel; <sup>7</sup> Central Laboratory, Maccabi Health Services, Rehovot, Israel; <sup>8</sup> Central Laboratory, Clalit Health Services, Haifa District, Israel; <sup>9</sup> Central Laboratory, Meuhedet Health Services, Lod, Israel; <sup>10</sup> Central Laboratory, Clalit Health Services, Tel-Aviv, Israel; <sup>11</sup> Veterinary Services, Ministry of Agriculture, Israel; <sup>12</sup> School of Public Health, University of Haifa, Haifa, Israel; <sup>13</sup> Sackler Faculty of Medicine, School of Public Health, Tel Aviv University, Israel

(Accepted 31 August 2011; first published online 1 November 2011)

### SUMMARY

The aim of the present study was to assess the recent trends in the epidemiology of non-typhoid *Salmonella* in Israel using a sentinel laboratory-based surveillance network. Between 1999 and 2009, 8758 *Salmonella* stool isolates were reported by five sentinel laboratories. There was a significant decrease in the incidence rate of *Salmonella* isolates from 70·5/100 000 in 1999 to 21·6/100 000 in 2005 followed by a slight increase to 30·3/100 000 in 2009. Of all *Salmonella*, 64·3% were isolated from children in the 0–4 years age group. Up to 2008, *S. Enteritidis* was the most prevalent serotype and in 2009 *S. Infantis* emerged as the most common *Salmonella* serotype. The decrease in the incidence of *S. Enteritidis* and *S. Typhimurium* and increase in *S. Infantis* among humans were associated with a similar trend among breeding flocks, which followed significant preventive interventions conducted against *S. Enteritidis* and *S. Typhimurium* infections in poultry. Tight surveillance and education of food handlers and consumers should be enhanced to reduce the foodborne transmission of *Salmonella* in Israel.

**Key words:** Antibiotic resistance, diarrhoea, epidemiology, foodborne infections, *Salmonella*.

### INTRODUCTION

Non-typhoid *Salmonella* are an important cause of enteric diseases and are associated with severe morbidity and excess mortality worldwide [1].

Salmonellosis is a foodborne disease, commonly manifested by acute enterocolitis, with sudden onset abdominal pain, diarrhoea, nausea, sometimes vomiting and fever [2]. Symptoms usually appear within 1–3 days following exposure and persist for 3–5 days. Serious bloodstream infections can occur, particularly in the very young or in the elderly, who are also at the highest risk for morbidity and mortality, depending on the non-typhoid serotypes [3, 4]. The extent of morbidity and mortality associated with

\* Author for correspondence: D. Cohen, MPH, PhD, Department of Epidemiology & Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel.  
(Email: dancohen@post.tau.ac.il)

non-typhoidal salmonellosis revealed the need for enhanced surveillance to follow sporadic (about 60–80% of all cases [2]) and outbreak source cases. Surveillance networks such as FoodNet and EnterNet have been established in the USA and Europe aiming at early detection of enteric disease outbreaks, detection of changes in the epidemiology of the different agents causing these outbreaks and identifying new genes encoding resistance to antibiotics.

The FoodNet surveillance run by the CDC's Emerging Infections Program reported a decrease in the incidence rate of *Salmonella* laboratory-confirmed infections when comparing 1996–1998 and 2007 data [5]. A decrease was also demonstrated in Europe by Denny *et al.* [6] and in England and Wales [7].

The incidence of salmonellosis in Israel increased from 31.6/100 000 in 1954 to 109.1/100 000 in 1996, decreased thereafter to 16.0/100 000 in 2005 and increased to 20.3/100 000 in 2009 [8].

Increasing antimicrobial resistance among *Salmonella* has been noted in several countries in the last decade [9, 10]. The incidence of multidrug-resistant *S. Typhimurium* and mostly multidrug-resistant *S. Typhimurium* DT104 rose markedly worldwide, including in Israel, during the 1990s and has thus become an increasing public health problem around the world [11–13].

A sentinel laboratory-based surveillance network was established in Israel in 1997 by the Israel Center for Disease Control (ICDC), which integrates information on *Salmonella* isolates from community and hospital laboratories and from the *Salmonella* National Reference Laboratory.

In this paper we present data generated by this network on agent and host-dependent characteristics of *Salmonella* enteric infections and antibiotic resistance patterns occurring in Israel in the last decade.

## MATERIALS AND METHODS

The sentinel laboratory-based surveillance network for bacterial enteric diseases (salmonellosis, shigellosis, campylobacteriosis) was established in Israel in 1997. Five community laboratories and three hospital-based laboratories representing the different geographical regions of Israel participate in this network: Haemek Medical Center (HMC) and Haifa HMO (HH) in northern Israel, Sheba Medical Center (SMC), Maccabi Dan District Community Laboratory (MD) and Clalit HMO Petah-Tikva (CPT) in central Israel, Hadassah (Ein Karem and Mount Scopus) (EK and

MS) medical centres and Meuhedet Community Laboratory (MCL) in Jerusalem District and Soroka Medical Center (SMC), Beer-Sheba in southern Israel. Clalit HMO Petah-Tikva Community Laboratory was added to the network in 2004. The population served by the five community laboratories (HMC, HH, MD, MCL, SMC) is well defined and covers 30.7% of the total Israeli population. The data presented in this paper refer to these five community laboratories for which the size and age distribution of the population they served was known and made possible the calculation of incidence rates. Demographic data on individuals with a positive stool sample for *Salmonella* and isolate characterization to the serogroup level were obtained from the sentinel laboratories and transferred to the ICDC, where they were integrated with the data on the further characterization of the isolates at the *Salmonella* National Reference Laboratory of the Ministry of Health.


The *Salmonella* National Reference Laboratory performed serotyping, phage-typing and antibiotic resistance testing. In the mid-2009, the performance of phage-typing was discontinued. This paper includes phage-type data until 2008.

*Salmonella* of the same serogroup and serotype isolated from the same individual within a month were counted only once. This paper refers to non-typhoidal *Salmonella* isolates.

Susceptibility of *Salmonella* isolates of the serotypes *S. Enteritidis*, *S. Typhimurium*, *S. Virchow* and *S. Hadar* to ampicillin (AMP), sulfamethoxazole–trimethoprim (SXT), ceftriaxone (CRO), chloramphenicol (C), ciprofloxacin (CIP) and tetracycline (TET) was determined at the *Salmonella* National Reference Laboratory of the Ministry of Health, by the Kirby–Bauer disk diffusion method [14]. The tests were performed on Muller–Hinton medium using Oxoid antimicrobial susceptibility disks (Oxoid, UK). Multidrug resistance was defined as resistance to three or more antimicrobial agents. These tests were performed for the years 2002–2007. The data on antibiotic resistance are presented for the total eight sentinel laboratories.

## Data analysis

Data analysis was performed using SAS software (release 9.1.3; SAS Institute Inc., USA). Information on the population size served by each sentinel laboratory was available by age group and sex. Incidence rates were calculated by year, month, age group and



**Fig. 1.** Incidence rate (per 100 000) of total *Salmonella* isolates and five most commonly identified *Salmonella* serotypes in five sentinel community laboratories, 1999–2009.

for the five most prevalent serotypes by dividing the number of individuals positive for *Salmonella* by the population covered by that laboratory.

We investigated time trends in the incidence rates in Israel from 1999 to 2009, using linear regression models.

## RESULTS

Between 1 January 1999 and 31 December 2009, data on 8758 isolates of *Salmonella* from stool specimens were reported to the ICDC by the five community laboratories according to the following breakdown: HH 2417 isolates (27.6%), SMC 1791 (20.4%), MCL 2046 (23.4%), MD 1783 (20.4%) and HMC 721 (8.2%).

### Age and gender distribution

Data on patient's age was achievable for 8649 *Salmonella* isolates. A total of 5558 (64.3%) isolates were from children in the 0–4 years age group. The proportions of isolates from the 5–14, 15–24, 25–34, 35–44, 45–54, 55–64 and  $\geq 65$  years age groups were 11.7% (1011 isolates), 5.4% (468), 4.7% (403), 3.1% (271), 3.6% (311), 2.7% (236) and 4.5% (391), respectively. Of children aged <5 years, 1683 (30.3%) were isolated in the first year of life, 2123 (38.2%) in the second year of life, 975 (17.5%) in the third and 777 (14.0%) in the fourth and fifth years of life. Of the 8620 isolates for whom data on patient's gender were available, 53.2% (4587 isolates) were from male patients.

### *Salmonella* serogroups, serotypes and phage types

The five most commonly identified serogroups were: *Salmonella* C1 (26.2%), *Salmonella* D (26.1%), *Salmonella* B (17.8%), *Salmonella* C2 (12.5%) and *Salmonella* E (2.0%). Of the total isolates, 11.8% were identified just by biochemical features and reported as *Salmonella* spp. without specification of serogroup.

The ten most commonly identified serotypes over the period 1999–2009 were: *S. Enteritidis* (26.5%), *S. Virchow* (12.7%), *S. Typhimurium* (8.8%), *S. Infantis* (8.4%), *S. Hadar* (7.3%), *S. Bredeney* (3.3%), *S. Montevideo* (3.0%), *S. Java* (2.2%), *S. 9,12:l,v:-* (2.1%) and *S. Newport* (1.9%). *S. Enteritidis* was the most commonly isolated serotype in all age groups.

Routine phage-typing was performed for *S. Enteritidis* and *S. Typhimurium* using the Israeli phage-typing scheme. The three most prevalent phage types among *S. Enteritidis* were B3 (47.4%), F3 (21.5%) and C8 (18.5%). The three most prevalent phage types among *S. Typhimurium* were 2(4+) (44.6%), Group 2 (22.3%) and R9 (9.0%).

### Time trends

There was a significant decrease in the incidence rate of *Salmonella* isolates from 70.5/100 000 in 1999 to 21.6/100 000 in 2005 ( $P$  value < 0.01) followed by an increase to 30.3/100 000 until 2009 ( $P$  value = 0.03 for trend) (Fig. 1). This time trend was evident in all five community laboratories (data not shown).

Table 1. Proportions of antibiotic resistance patterns of *Salmonella* serotypes, 2002–2007

	AMP		SXT		CRO		C		CIP		TET	
	R (%)	n	R (%)	n	R (%)	n	R (%)	n	R (%)	n	R (%)	n
<i>S. Typhimurium</i>	99 (45.2)	219	10 (4.6)	219	0 (0.0)	219	83 (37.9)	219	0 (0.0)	219	116 (53.0)	219
<i>S. Enteritidis</i>	23 (3.7)	617	4 (0.6)	617	2 (0.3)	617	4 (0.6)	617	0 (0.0)	617	11 (1.8)	617
<i>S. Virchow</i>	41 (9.4)	435	165 (37.9)	435	0 (0.0)	435	140 (32.2)	435	0 (0.0)	435	171 (39.3)	435
<i>S. Hadar</i>	36 (16.4)	219	11 (5.0)	219	0 (0.0)	219	1 (0.5)	219	1 (0.5)	219	194 (88.6)	219

R, Resistant; AMP, ampicillin; SXT, sulfamethoxazole–trimethoprim; CRO, ceftriaxone; C, chloramphenicol; CIP, ciprofloxacin; TET, tetracycline.

Table 2. Antibiotic resistance patterns of *Salmonella* serotypes, 2002–2007

	Pattern	AMP	SXT	CRO	C	CIP	TET	n (%)
<i>S. Typhimurium</i> (n=219 isolates tested)	1	R	S	S	R	S	R	79 (36.1)
	2	S	S	S	S	S	R	27 (12.3)
	3	R	S	S	S	S	S	11 (5.0)
<i>S. Virchow</i> (n=435 isolates tested)	1	S	R	S	R	S	R	112 (25.8)
	2	R	R	S	R	S	R	25 (5.8)
	3	S	R	S	S	S	R	21 (4.8)
	4	R	S	S	S	S	S	8 (1.8)
<i>S. Enteritidis</i> (n=617 isolates tested)	1	R	S	S	S	S	S	16 (2.6)
	2	S	S	S	S	S	R	5 (0.8)
<i>S. Hadar</i> (n=219 isolates tested)	1	S	S	S	S	S	R	152 (69.4)
	2	R	S	S	S	S	R	33 (15.1)

AMP, Ampicillin; SXT, sulfamethoxazole–trimethoprim; CRO, ceftriaxone; C, chloramphenicol; CIP, ciprofloxacin; TET, tetracycline.

The decrease in the incidence rate of *Salmonella* isolates from 1999 to 2005 and the increase from 2005 and onwards were consistent in all age groups and in both males and females (data not shown). The highest incidence rates throughout the years were observed in the 0–4 years age group, which also experienced the most significant decrease from 437.7/100 000 in 1999 to 121.0/100 000 in 2005 followed by and increase to 176.4/100 000 in 2009. Other age groups showed the same trends with about tenfold lower incidence rates.

There was a clear pattern of seasonality in the number of *Salmonella* isolates over the years with an increase in April–May, a peak in August and a decrease thereafter. A shifting in the most prevalent serotype was observed in 2009. The incidence of *S. Enteritidis*, the most prevalent serotype during 1999–2008, decreased from 14.0/100 000 in 1999 to 4.7/100 000 in 2007 and increased to 7.1/100 000 in 2009. The incidence of *S. Infantis* increased markedly from 0.6/100 000 in 2006 to 10.0/100 000 in 2009, becoming the most prevalent *Salmonella* serotype in Israel in 2009 (Fig. 1).

### Antibiotic resistance

Between 2002 and 2007, 1490 (59.8%) of 2491 isolates were tested for antibiotic resistance (617 *S. Enteritidis*, 435 *S. Virchow*, 219 *S. Typhimurium*, 219 *S. Hadar*). The proportions of antibiotic resistance to these antibiotics are presented in Table 1. *S. Typhimurium* was highly resistant to tetracycline, ampicillin and chloramphenicol. *S. Virchow* was resistant to tetracycline, sulfamethoxazole–trimethoprim and chloramphenicol. *S. Hadar* was resistant to tetracycline. Over 95% of the *S. Enteritidis* isolates were susceptible to all six antibacterial drugs. Of 1490 isolates tested for antibiotic resistance, 15.4% were multidrug resistant (resistant to three or more antimicrobial agents). Multidrug resistance was found in 37.9% of *S. Typhimurium* strains, 32.6% of *S. Virchow* strains, 0.5% of *S. Enteritidis* and in 0.5% of *S. Hadar* strains.

Common antibiotic resistance patterns are presented in Table 2. The most frequent pattern (36.1%) belonged to *S. Typhimurium* isolates which were

resistant to ampicillin, chloramphenicol and tetracycline (R-Type ACT). Another common resistance pattern was that of *S. Virchow* isolates which simultaneously showed resistance to sulfamethoxazole–trimethoprim, chloramphenicol and tetracycline (25.8%).

## DISCUSSION

In this article we report on 11-year data generated by a sentinel, laboratory-based surveillance network of salmonellosis established in Israel in 1997. These data show that the incidence of salmonellosis in Israel decreased markedly from 70.5/100 000 in 1999 to 21.6/100 000 in 2005, and increased to 30.3/100 000 in 2009. The parallel incidence rates reported by the Department of Epidemiology of the Israel Ministry of Health based on the national passive surveillance system which was established at the beginning of the 1950s, were 63.0/100 000 in 1999, 16.0/100 000 in 2005 and 20.3/100 000 in 2009 [8]. Although both systems of surveillance identified a similar trend in the incidence of salmonellosis in Israel, the figures yielded by the national passive surveillance system were lower and probably reflect under-reporting. Moreover, by integrating data on the isolation of *Salmonella* at the sentinel laboratories with information related to patients (gender, age, address, etc.) and characterization of isolates at the National Reference Centers of the Ministry of Health, the sentinel laboratory-based surveillance could show that the decrease in the incidence of non-typhoidal salmonellosis encompassed both genders and especially children aged 0–4 years and could display the changes in the relative importance of the leading *Salmonella* serotypes throughout 11 years of surveillance.

A decrease in the incidence of non-typhoidal salmonellosis in the last decade was also seen in other countries. According to FoodNet, the incidence rate of *Salmonella* laboratory-confirmed infections decreased by 8%, comparing data from 1996–1998 and 2007 [5]. Data from Denny *et al.* showed a similar trend [6]. In England and Wales, the estimated cases of non-typhoidal *Salmonella* fell to less than half between 1992 and 2000 [7]. The incidence of *Salmonella* infections in Israel is still higher than that reported from other developed countries. In the USA, the reported incidence rate was 14.9/100 000 in 2007 [5], in comparison with 27.2/100 000 in the present study, for the same year. We cannot rule out the possibility that this difference could be at least in part due to

differences in referral of specimens, testing for pathogens or other reasons.

*Salmonella* was consistently most common in children aged <5 years. Similar age distributions have been reported in the USA [5, 15–17] and Australia [18]. The reason for the high incidence rate in this age group has been described previously [19] and includes the high susceptibility of the intestinal microflora since the immune system is still developing and because this age group is more likely than others to expose infected items to their mouths.

We have shown a marked pattern of seasonality of salmonellosis, with incidence rates rising in the warm months and decreasing in the cold months, as expected. This seasonal pattern was also demonstrated in the USA [15, 16] and Canada [11].

*S. Enteritidis* was the most common serotype detected of all serotypes in the 11 years of surveillance. Other prevalent serotypes were *S. Virchow*, *S. Typhimurium*, *S. Infantis*, *S. Hadar*, *S. Bredeney*, *S. Montevideo*, *S. Java*, *S. 9,12:l,v:-* and *S. Newport*, by rank. According to the FoodNet Emerging Infections Program, in 2007, the most common serotypes in the USA were: *S. Enteritidis*, *S. Typhimurium*, *S. Newport*, *S. 1,4,[5],12:i:-*, *S. Javiana*, *S. Heidelberg* and *S. Montevideo* [5]. The WHO Global Salm-Surv country databank, where 31 countries submitted data on 125 745 human *Salmonella* isolates worldwide, reported that during 2002, *S. Enteritidis* was also the most common serotype among humans, accounting for 65% of all isolates [20]. After *S. Enteritidis*, the nine most common serotypes in humans were *S. Typhimurium*, *S. Newport*, *S. Heidelberg*, *S. Infantis*, *S. Hadar*, *S. Virchow*, *S. Javiana*, *S. Saintpaul* and *S. Montevideo*, by rank [20].

*S. Enteritidis* is related to foodborne outbreaks and sporadic cases of human gastrointestinal diseases worldwide [21] are mostly associated with under-cooked eggs [22–25]. In Germany, the decline in the incidence rate of *Salmonella* between 2001 and 2008 was related to a decrease in the incidence rate of *S. Enteritidis* [26].

The Public Health Laboratory Information System (PHLIS), a national *Salmonella* surveillance system, which collects data on reported laboratory-confirmed *Salmonella* isolates in the USA, reported that *S. Typhimurium* and *S. Enteritidis* both declined substantially (28% and 34%, respectively) between 1995 and 2005 [17]. The most marked decrease in our study was observed for *S. Typhimurium*, consistently

throughout the surveillance period, with an incidence rate of 5.3/100 000 in 1999 to 0.8/100 000 in 2009. The FoodNet surveillance system in the USA also reported a decrease in the incidence of *S. Typhimurium* [5]. In Europe, a decline in *S. Enteritidis* was observed between 1998 and 2005 [27] and in *S. Typhimurium* between 1998 and 2003 [28].

The decrease in the incidence of *S. Typhimurium* is of particular importance due to the high rate of antibiotic resistance acquisition of this serotype.

Between 1999 and 2006, *S. Infantis* was ranked fifth among *Salmonella* serotypes in Israel. Since December 2007, the incidence of this serotype increased markedly and in 2009, *S. Infantis* became the most prevalent *Salmonella* serotype in Israel. Worldwide, *S. Infantis* was ranked fifth among *Salmonella* serotypes in 2002 [20] and in the USA, *S. Infantis* was ranked ninth between 1987 and 1997 [15].

The significant decrease in salmonellosis caused by *S. Enteritidis* and *S. Typhimurium* and the emergence of *S. Infantis* in Israel as the most prevalent serotype parallel similar changes in the incidence and distribution of *Salmonella* serotypes occurring at the level of the main natural reservoir of *Salmonella*, i.e. poultry. Actions taken to reduce *S. Enteritidis* and *S. Typhimurium* infections in poultry as tight surveillance of all breeding flocks and hatcheries, culling or treatment of all flocks infected with *S. Enteritidis* or *S. Typhimurium*, improvement of biosecurity and infrastructure, and systematic immunization against *S. Typhimurium* and *S. Enteritidis* started in 1994 and 1996, led most probably to the marked decrease in the incidence of these serotypes in poultry. In 1996, *S. Enteritidis* or *S. Typhimurium* were isolated from 33.6% of the breeding flocks and in 2009 only 0.4% were positive to one of these two pathogens (E. Berman, personal communication). Since 2008, *S. Infantis* has been the most frequent serotype among breeding flocks, accounting for 27.9% of all poultry between June 2008 and May 2009 (E. Berman, personal communication). The temporal association between the increase in incidence of *S. Infantis* in breeding flocks and in humans and the similar pulsed-field electrophoresis profiles of *S. Infantis* human and poultry isolates [29] reveal the important role of the animal reservoir and the food-borne transmission of *Salmonella* in Israel.

The incidence rate of *S. Virchow* infections was ranked second over the 11 years of surveillance in Israel. The high prevalence of *S. Virchow* among

non-typhoid *Salmonella* serotypes is unique to Israel [30]. In the USA and Europe, *S. Virchow* accounts for <1% and <5% of total non-typhoid *Salmonella* isolates, respectively [30] and in 2002, *S. Virchow* was ranked only seventh among human *Salmonella* isolates worldwide [20]. Physicians should pay attention to isolation of *S. Virchow* since it tends to invade the bloodstream and to cause invasive infection, especially in infants aged <2 years [3]. We will follow this pattern to discover whether *S. Enteritidis* will regain its position of leading importance among the *Salmonella* serotypes isolated in Israel.

The data we provide on the distribution of the *S. Enteritidis* and *S. Typhimurium* phage types are based on the Israeli phage-typing scheme, which prevents international comparisons, except for the incidence of *S. Typhimurium* phage type 2(4+) (according to the local scheme) which was documented as being identical to DT104 (definitive phage-type 104) [13]. The proportion of this *S. Typhimurium* phage type declined from 56.0% in 1999 to 35.1% in 2008. The reduction of DT104 phage type is of public health importance due to the resistance of this specific phage type to multiple antibacterial drugs.

We found that *S. Typhimurium* and *S. Virchow* were more resistant to antibiotics compared to *S. Enteritidis* and *S. Hadar*. *S. Typhimurium* and *S. Virchow* were also highly multidrug resistant. High rates of multidrug-resistant *S. Virchow* were also reported in Denmark for the period 2003–2005 [31].

In spite of being the most prevalent serotype, *S. Enteritidis* did not acquire antibiotic resistance over the years, as documented by a comparison of the findings of a study conducted in southern Israel between 1994 and 1996, when over 95% of *S. Enteritidis* isolates exhibited susceptibility to various antibiotic drugs [13]. Reports from the USA also indicate a low resistance rate of *S. Enteritidis* [32]. During 2002–2007, the period for which antibiotic resistance patterns are presented in this paper, *S. Infantis* was not tested routinely for antibiotic resistance. However, data on *S. Infantis* resistance patterns in Israel including 71 randomly selected isolates of *S. Infantis* which were identified in Israel during 2007–2009 (21 human sources, 28 poultry sources, 22 food sources) and were tested for antibiotic resistance showed that the dominant clone of *S. Infantis* was multidrug resistant (96%), with a combined resistance pattern to nalidixic acid, nitrofurantoin and tetracycline, with or without additional resistance to trimethoprim–sulfamethoxazole [29].

It should be borne in mind that the laboratory-based surveillance system underestimates the real burden of salmonellosis. Only a fraction of individuals with gastroenteritis consult a physician, and only a small part of them have a stool culture performed. A population survey performed by FoodNet reported a ratio of 1:39 between laboratory-confirmed cases and *Salmonella* infections in the community [33].

In conclusion, despite the significant decrease in incidence rates over the last 11 years, *Salmonella* infections are still common in Israel with specific emerging serotypes such as *S. Infantis* which have become more prevalent than *S. Enteritidis* and *S. Typhimurium*. There is still a clear need for improvement of hygiene and sanitary standards in breeding flocks and hatcheries. It is expected that these actions, coupled with enhanced education of food handlers and consumers with regard to prevention of foodborne disease transmission will further decrease the incidence of salmonellosis in Israel.

#### ACKNOWLEDGEMENTS

We thank Nadia Pekurovski for her assistance in the data collection of the sentinel laboratory-based surveillance network and Anneke Ifrah for her contribution in reviewing this study summary.

#### DECLARATION OF INTEREST

None.

#### REFERENCES

1. Helms M, *et al.* Short and long term mortality associated with foodborne bacterial gastrointestinal infections: registry based study. *British Medical Journal* 2003; **326**: 357.
2. Heymann DL. *Control of Communicable Diseases Manual*, 18th edn. Washington DC: American Public Health Association, 2004, pp. 469–473.
3. Weinberger M, *et al.* Blood invasiveness of *Salmonella enterica* as a function of age and serotype. *Epidemiology and Infection* 2004; **132**: 1023–1028.
4. Jones TF, *et al.* Salmonellosis outcomes differ substantially by serotype. *Journal of Infectious Disease* 2008; **198**: 109–114.
5. Centers for Disease Control and Prevention (CDC). Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food – 10 states, 2007. *Morbidity and Mortality Weekly Report* 2008; **57**: 366–370.
6. Denny J, *et al.* Zoonotic infections in Europe: trends and figures – a summary of the EFSA-ECDC annual report. *Eurosurveillance* 2007; **12**: E071220.6.
7. Adak GK, *et al.* Trends in indigenous foodborne disease and deaths, England and Wales: 1992 to 2000. *Gut* 2002; **51**: 832–841.
8. Israel Center for Disease Control (ICDC) and the Department of Epidemiology, Public Health Services, Ministry of Health. Notifiable infectious diseases in Israel: 60 years of surveillance, 1951–2010. Tel Hashomer, Israel (in press).
9. Cailhol J, *et al.* Trends in antimicrobial resistance phenotypes in non-typhoid *Salmonellae* from human and poultry origins in France. *Epidemiology and Infection* 2006; **134**: 171–178.
10. Martin LJ, *et al.* Increased burden of illness associated with antimicrobial-resistant *Salmonella enterica* serotype Typhimurium infections. *Journal of Infectious Diseases* 2004; **189**: 377–384.
11. Ford MW, *et al.* A descriptive study of human *Salmonella* serotype Typhimurium infections reported in Ontario from 1990 to 1998. *Canadian Journal of Infectious Disease* 2003; **14**: 267–273.
12. Helms M, *et al.* International *Salmonella* Typhimurium DT104 infections, 1992–2001. *Emerging Infectious Diseases* 2005; **11**: 859–867.
13. Metzger E, *et al.* Emergence of multidrug-resistant *Salmonella enterica* serotype Typhimurium phage-type DT104 among *Salmonella* causing enteritis in Israel. *Epidemiology and Infection* 1998; **121**: 555–559.
14. Bauer AW, *et al.* Antibiotic susceptibility testing by a standardized single disk method. *American Journal of Clinical Pathology* 1966; **45**: 493–496.
15. Olsen SJ, *et al.* The changing epidemiology of *Salmonella*: trends in serotypes isolated from humans in the United States, 1987–1997. *Journal of Infectious Diseases* 2001; **183**: 753–761.
16. Centers for Disease Control and Prevention (CDC). Foodborne Diseases Active Surveillance Network (FoodNet): FoodNet surveillance report for 2004 (final report). Atlanta, GA: US Department of Health and Human Services, 2006.
17. Centers for Disease Control and Prevention (CDC). *Salmonella* surveillance: annual summary, 2005. Atlanta, GA: US Department of Health and Human Services, 2006.
18. Owen R, *et al.* Australia's notifiable diseases status, 2005: annual report of the National Notifiable Diseases Surveillance System. *Communicable Diseases Intelligence* 2007; **31**: 1–70.
19. Mountzouris KC, *et al.* Intestinal microflora of human infants and current trends for its nutritional modulation. *British Journal of Nutrition* 2002; **87**: 405–420.
20. Galanis E, *et al.* Web-based surveillance and global *Salmonella* distribution, 2000–2002. *Emerging Infectious Diseases* 2006; **12**: 381–388.
21. Fernandes SA, *et al.* *Salmonella* serovars isolated from humans in São Paulo State, Brazil, 1996–2003. *Revista do Instituto de Medicina Tropical de São Paulo* 2006; **48**: 179–184.

22. **Delarocque-Astagneau E, et al.** Risk factors for the occurrence of sporadic *Salmonella* enterica serotype enteritidis infections in children in France: a national case-control study. *Epidemiology and Infection* 1998; **121**: 561–567.
23. **Morse DL, et al.** Outbreak and sporadic egg-associated cases of *Salmonella* enteritidis: New York's experience. *American Journal of Public Health* 1994; **84**: 859–860.
24. **Mishu B, et al.** Outbreaks of *Salmonella* enteritidis infections in the United States, 1985–1991. *Journal of Infectious Diseases* 1994; **169**: 547–552.
25. **Centers for Disease Control and Prevention (CDC).** Outbreaks of *Salmonella* serotype enteritidis infection associated with eating shell eggs—United States, 1999–2001. *Morbidity and Mortality Weekly Report* 2003; **51**: 1149–1152.
26. **Frank C, et al.** Marked decrease in reporting incidence of salmonellosis driven by lower rates of *Salmonella* Enteritidis infections in Germany in 2008: a continuing trend. *Eurosurveillance* 2009; **14**: 19154.
27. **Fisher IS.** *Salmonella* Enteritidis in Europe: Surveillance report from the Enter-net database 1998–2005.
28. **Fisher IS, et al.** International trends in *Salmonella* serotypes 1998–2003 – a surveillance report from the Enter-net international surveillance network. *Euro-surveillance* 2004; **9**: 45–47.
29. **Gal-Mor O, et al.** Multidrug-resistant *Salmonella* enterica serovar Infantis, Israel. *Emerging Infectious Diseases* 2010; **16**: 1754–1757.
30. **Weinberger M, et al.** Recent trends in the epidemiology of non-typhoid *Salmonella* and antimicrobial resistance: the Israeli experience and worldwide review. *Current Opinion in Infectious Diseases* 2005; **18**: 513–521.
31. **Bagger-Skjøt L, et al.** Less frequent *Salmonella* serovars as a reservoir of antimicrobial resistance. *Journal of Antimicrobial Chemotherapy* 2007; **59**: 814–815.
32. **NARMS.** The National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): Human Isolates Final Report, 2004. Atlanta, Georgia: U.S. Department of Health and Human Services, CDC, 2007.
33. **Voetsch AC, et al.** FoodNet estimate of the burden of illness caused by nontyphoid *Salmonella* infections in the United States. *Clinical Infectious Diseases* 2004; **38** (Suppl. 3): S127–134.